How to Predict Hepatotoxicity and Drug Clearance Ahead of Clinical Trials Using Liver-on-a-Chip
Webinar Series 2 Episode 2:
Current in vitro approaches for investigational toxicology, drug metabolism (DMPK) and safety are limited and are not fully representative of human response; therefore, drugs showing acceptable preclinical toxicity often fail in human clinical trials, and accurately predicting human drug exposure for new compounds is challenging and costly.
Dr Tomasz Kostrzewski, Director of Biology at CN Bio.
